Avalanche Biotechnologies CEO Laurent Fischer's 2022 pay falls 68% to $2.9M

Avalanche Biotechnologies reports 2022 executive compensation

By ExecPay News

Published: April 25, 2023

Avalanche Biotechnologies reported fiscal year 2022 executive compensation information on April 25, 2023.
In 2022, seven executives at Avalanche Biotechnologies received on average a compensation package of $1.3M, a 53% decrease compared to previous year.
Average pay of disclosed executives at Avalanche Biotechnologies
Laurent Fischer, Chief Executive Officer, received $2.9M in total, which decreased by 68% compared to 2021. 66% of Fischer's compensation, or $1.9M, was in option awards. Fischer also received $329K in non-equity incentive plan, $646K in salary, as well as $2.1K in other compensation.
For fiscal year 2022, the median employee pay was $169,590 at Avalanche Biotechnologies. Therefore, the ratio of Laurent Fischer's pay to the median employee pay was 17 to one.
Setareh Seyedkazemi, Chief Development Officer, received a compensation package of $1.5M. 41% of the compensation package, or $629K, was in option awards.
Richard Beckman, Chief Medical Officer, earned $1.4M in 2022.
Kishor Peter Soparkar, Chief Operating Officer, received $1.3M in 2022, which decreases by 46% compared to 2021.
John Rakow, Chief Financial Officer, earned $1M in 2022.
Rupert D'Souza, Chief Financial Officer, received $636K in 2022, which increases by 14% compared to 2021.
Linda Rubinstein, Chief Financial Officer, earned $112K in 2022.

Related executives

Laurent Fischer

Avalanche Biotechnologies

Chief Executive Officer

Linda Rubinstein

Avalanche Biotechnologies

Chief Financial Officer

Richard Beckman

Avalanche Biotechnologies

Chief Medical Officer

Setareh Seyedkazemi

Avalanche Biotechnologies

Chief Development Officer

Kishor Soparkar

Avalanche Biotechnologies

Chief Operating Officer

Rupert D'Souza

Avalanche Biotechnologies

Chief Financial Officer

John Rakow

Avalanche Biotechnologies

Chief Financial Officer

You may also like

Source: SEC filing on April 25, 2023.